Related by context. All words. (Click for frequent words.) 71 AEZS 69 MORAb 68 targeting CD# 68 OXi# 68 ARRY 67 JVRS 67 Preclinical studies 67 preclinical efficacy 66 GRN#L 66 pan HDAC inhibitor 66 mertansine 66 xenograft models 66 PSMA ADC 66 solithromycin 66 HGS ETR1 66 ENMD # 66 milatuzumab 66 HuLuc# 66 antiviral activity 66 VQD 65 preclinical studies 65 AEGR 65 oral prodrug 65 EpCAM 65 APOPTONE 65 histone deacetylase inhibitor 65 MT# MEDI 65 preclinically 65 AEG# 65 neratinib 65 HGS ETR2 65 nucleotide analog 64 enzastaurin 64 INCB# [001] 64 CUDC 64 liposomal formulation 64 Panzem 64 huN# DM1 64 Tarvacin 64 decitabine 64 PEG SN# 64 davunetide intranasal AL 64 OMP #M# 64 CD# antibody [001] 64 mda 7 64 BAL# [001] 64 CRx 64 favorable pharmacokinetic profile 64 evaluating tivozanib 64 oncolytic virus 64 antitumor 64 protein kinase inhibitor 64 ISIS # 63 HQK 63 BRAF inhibitor 63 lintuzumab 63 ganetespib 63 huC# DM4 63 CERE 63 polymerase inhibitor 63 SCH # 63 mapatumumab 63 alvespimycin 63 CCR9 63 XmAb# 63 telaprevir VX 63 FLT3 63 Carfilzomib 63 Thiovir 63 elesclomol 63 VEGF receptor 63 HCV protease 63 hematological cancers 63 RGB # 63 lumiliximab 63 bortezomib Velcade ® 63 T#I [002] 63 NKTR 63 demonstrated antitumor activity 63 Azedra 63 Bezielle 63 orally bioavailable 63 trastuzumab Herceptin R 63 Enzastaurin 63 potent antitumor activity 63 CBLC# 63 4SC 63 non nucleoside inhibitor 63 virus HCV protease inhibitor 63 PARP inhibitor 63 antitumor activity 62 Symadex 62 axitinib 62 Vitaxin 62 HCV protease inhibitors 62 Actilon 62 histone deacetylase HDAC inhibitor 62 Omacetaxine 62 vitro studies 62 Sym# 62 vivo efficacy 62 PXD# 62 bendamustine 62 antitumor effects 62 Valortim R 62 GW# [003] 62 seliciclib 62 Varespladib 62 PRTX 62 inhibitor RG# 62 pertuzumab 62 preclinical models 62 viral kinetics 62 flavopiridol 62 radezolid 62 vitro cytotoxicity 62 PCK# 62 Multimeric 62 obatoclax 62 CYT# potent vascular disrupting 62 MAGE A3 ASCI 62 trastuzumab Herceptin 62 delta isoform 62 anti CD3 62 induce apoptosis 62 induces apoptosis 62 standard chemotherapy regimen 62 drug conjugate 62 vascular disrupting agent 62 anti leukemic 62 potent inhibition 62 HGS# 62 elacytarabine 62 intratumoral injection 62 thymalfasin 62 antisense inhibitors 62 oral FTY# 62 XL# inhibits 62 MAGE A3 62 entinostat 61 CTLA 4 61 pro apoptotic 61 EGFR HER2 61 PRT# 61 bortezomib 61 cMET 61 Debio 61 Phase Ib clinical 61 cisplatin resistant 61 imetelstat 61 NS#/#A protease 61 cilengitide 61 fosbretabulin 61 nitazoxanide 61 survivin 61 forodesine 61 antibody MT# 61 antisense inhibition 61 EGFr 61 Tarceva TM 61 Aplidin R 61 Gleevec resistant 61 Virulizin ® 61 CD4 monoclonal antibody 61 Nanobody 61 Tarvacin TM 61 TRAIL R2 61 IL #E 61 ON #.Na 61 humanized monoclonal antibodies 61 AAV2 61 DNA intercalator 61 immunotoxins 61 JAK inhibitor 61 TTR gene 61 anti amnesic 61 telomerase therapeutic 61 Phase Ib II 61 HCV nucleotide polymerase inhibitor 61 erlotinib Tarceva ® 61 EndoTAG TM -1 61 CR# vcMMAE 61 investigational humanized monoclonal antibody 61 ongoing Phase 1b 61 HSP# inhibitor 61 PI3K inhibitor 61 GM CSF 61 OncoVEX GM CSF 61 selective inhibition 61 Xanafide 61 HDAC Inhibitor 61 Irinotecan 61 CGEN # 61 immunomodulator 61 CYT# 61 IFN α 61 Imprime PGG 61 Insegia 61 IMC A# 61 oncolytic 61 CanAg 61 tubulin inhibitor 61 Aplidin 61 PSN# [002] 61 HuMax CD# 61 thalidomide Thalomid 61 IDX# 61 CRLX# 61 phase IIb trial 61 ARQ 61 K ras mutations 61 Phase 2a trial 61 angiogenesis inhibitor 61 TRAIL induced apoptosis 61 CYC# 61 Traficet EN 61 #D#C# 60 GRN# 60 ATL/TV# 60 Preclinical Study 60 depsipeptide 60 Curaxin CBLC# 60 DXL# 60 Copegus ribavirin 60 AAG geldanamycin analog 60 Zybrestat 60 MEK inhibitor 60 Hedgehog pathway 60 humanized monoclonal antibody 60 antibody MAb 60 CCX# 60 immunotoxin 60 Angiolix 60 IMGN# 60 NY ESO 60 CTGF 60 HDACi 60 mouse xenograft models 60 HCV protease inhibitor 60 proteasome inhibitor 60 immunostimulatory 60 Pharmacokinetics PK 60 Alocrest 60 Fc fusion protein 60 ITMN 60 NXL# 60 humanized anti 60 Cotara 60 immunomodulating 60 lexidronam injection 60 HspE7 60 LY# [002] 60 rhIL 7 60 IMMU 60 selective kinase inhibitor 60 multi kinase inhibitor 60 pegylated liposomal doxorubicin 60 IMA# 60 MET amplification 60 CIMZIA TM 60 Janus kinase 60 CORT # 60 murine monoclonal antibody 60 immune modulation 60 protein tyrosine phosphatase 1B 60 Vandetanib 60 MYDICAR ® 60 INNO 60 HER2 overexpression 60 PROSTVAC VF 60 CD# monoclonal antibody 60 Triolex 60 selective inhibitor 60 WT1 60 PROCHYMAL 60 CD# CEA 60 replicon 60 Epratuzumab 60 angiogenesis inhibition 60 potent inhibitor 60 TREANDA 60 oral antiviral 60 Seliciclib 60 PKC# 60 ImmunoVEX HSV2 60 selective agonist 60 bevacizumab Avastin ® 60 PS# [001] 60 Aurora kinase 60 MEK ERK 60 antiangiogenic activity 60 gefitinib Iressa 60 Exherin TM 60 Onconase 60 HCV replicon 60 HCV replication 60 cytotoxin 60 Pradefovir 60 nonclinical studies 60 OHR/AVR# 60 Valortim 60 PEG Interferon lambda 60 HuMax EGFr 60 riociguat 60 anti proliferative 60 busulfan 60 MEK inhibitors 60 SAR# [004] 60 Cethromycin 60 Phase Ib clinical trials 60 OncoVex 60 trodusquemine 60 ENMD 60 alpha folate receptor 60 oral Hsp# inhibitor 60 docetaxel chemotherapy 60 vascular disrupting agents 60 MGCD# [001] 60 SIRT2 60 IgG1 antibody 60 anticancer activity 60 CTAP# Capsules 60 IMP# 60 Posiphen 60 SPC# [001] 60 glioblastoma multiforme GBM 60 cytoprotective 60 monoclonal antibody MAb 60 alkylating agent 60 monoclonal antibody mAb 59 effector function 59 Lenocta 59 μg dose 59 Kinase Inhibitor 59 Cloretazine 59 BiTE antibodies 59 Quinamed 59 antitumor effect 59 CCR2 59 HER2/neu 59 Monoclonal Antibody 59 Factor VIIa 59 LY# [003] 59 adenoviral 59 R#/MEM # 59 hedgehog pathway 59 tanespimycin 59 DAVANAT 59 Telaprevir VX 59 pharmacodynamic properties 59 MGd 59 therapeutic monoclonal antibody 59 EGEN 59 Factor Receptor 59 inhibit metastasis 59 DiLA2 liposomes 59 M2 subunit 59 PI3K Akt 59 pomalidomide 59 #ME# 59 JAK3 59 HCV NS5B polymerase 59 potent cytotoxic 59 novel peptide 59 adecatumumab MT# 59 IGF 1R 59 antiproliferative effects 59 Amrubicin 59 CA4P 59 #th Annual Interscience 59 midstage trials 59 BZL# 59 BiTE antibody MT# 59 YONDELIS 59 non nucleoside HCV 59 orally administered inhibitor 59 ProMune 59 sorafenib Nexavar 59 Beta catenin pathway 59 velafermin 59 gemcitabine carboplatin 59 Mesothelin 59 isoform selective 59 cisplatin gemcitabine 59 interferon lambda 59 mAb 59 Apoptone 59 EGFRvIII 59 ANG# 59 ALN TTR 59 HDAC inhibitor 59 Zalypsis 59 systemically administered 59 potently inhibited 59 elotuzumab 59 Removab 59 antitumor efficacy 59 MCSP respectively 59 FluCide 59 DermaVir Patch 59 tumor specific antigen 59 nanoviricides 59 azacytidine 59 A3 adenosine receptor 59 antiangiogenic 59 Sphingomab 59 tolerability profile 59 Hsp# Inhibitor 59 alpha7 59 miR #a [002] 59 peptide antigens 59 Phase 1b clinical trials 59 Vidofludimus 59 Blinatumomab 59 dacetuzumab 59 antisense drug 59 novel VDA molecule 59 JAK inhibitors 59 bone metastasis 59 Immunohistochemical analysis 59 celgosivir 59 vismodegib 59 tremelimumab 59 otelixizumab 59 P#X# 59 tesmilifene 59 TransVax TM 59 BiTE R 59 c MYC 59 DepoVax 59 teriflunomide 59 IFN alpha 59 amrubicin 59 ALN VSP 59 secretory phospholipase A2 sPLA2 59 VEGFR2 59 BNC# 59 Vaxfectin 59 anti CD3 antibody 59 beta Estradiol 59 alpha antagonist 59 glycogen synthase kinase 59 GRNVAC1 59 sunitinib Sutent ® 59 Kahalalide F 59 imatinib Gleevec ® 59 orally dosed 59 nucleoside analog 59 S/GSK# 59 volociximab 59 EZN 59 GVAX 59 chemotherapeutic drug 59 PLX# 59 immunomodulatory 59 Telcyta 59 epithelial tumors 59 immune modulator 59 XL# XL# 59 Universal Flu Vaccine 59 subcutaneous PRO 59 Ozarelix 59 ProSavin 59 Bafetinib 59 vitro experiments 59 CDDO Im 59 Phase #/#a trial 59 ALTU 59 Phase 1b 59 initiate Phase 1b 59 phase IIb clinical 59 HDAC inhibitors 59 humanized monoclonal 59 cyclin dependent kinases CDKs 59 TG# [001] 59 BiTE 59 RG# ITMN 59 PEGylated 59 Palifosfamide 59 phase Ib 59 samarium Sm 59 neuroprotectant 59 Bavituximab 59 ELACYT 58 multiple myeloma MM 58 mTOR inhibitors 58 Sapacitabine 58 HGS ETR1 mapatumumab 58 selective modulator 58 lentiviral vector 58 Epidermal Growth Factor Receptor 58 cancer immunotherapies 58 sorafenib tablets 58 CD# expressing 58 SRT# [003] 58 immune modulatory 58 HCV SPRINT 58 Oritavancin 58 MAb 58 Erlotinib 58 GLYX 58 Randomized Phase 58 BCIRG 58 TLR9 58 gemcitabine cisplatin 58 sodium glucose cotransporter 58 CIMZIA ™ 58 EGF receptor 58 nanomolar 58 LHRH receptor 58 anti EGFR antibody 58 masitinib 58 kinase inhibitor 58 TLR9 agonist 58 LBH# 58 BRIM3 58 E#F# 58 FGFR 58 Antiviral Activity 58 AKT inhibitor 58 IGF 1R inhibitor 58 BiovaxID 58 tumor antigen 58 vidofludimus 58 NEUGENE 58 anti CTLA 58 resolvin 58 MVA BN R 58 etoposide 58 phase IIa clinical 58 CDK inhibitor 58 ADXS# 58 HER2 antibody 58 radiation sensitizer 58 Tyrima 58 CD# antibodies 58 Pertuzumab 58 cancer vaccine Norelin 58 AQ4N 58 novel topoisomerase 58 tumor xenograft models 58 menadione 58 NEUGENE R 58 Tarvacin Anti Viral 58 PEGylated interferon 58 EGFR receptor 58 GAP #B# 58 immune stimulatory 58 calcitriol 58 investigational monoclonal antibody 58 IRX 2 58 PF # [001] 58 tubulin polymerization 58 telomerase inhibitor drug 58 hA# 58 rilonacept 58 novel histone deacetylase 58 R roscovitine 58 AP# [003] 58 iniparib BSI 58 Dapagliflozin 58 pharmacokinetic PK profile 58 recurrent glioblastoma multiforme 58 thymidylate synthase TS 58 PKCi 58 BAY #-# 58 INT# [002] 58 Velcade bortezomib 58 potent anti angiogenic 58 metastatic renal cell carcinoma 58 brostallicin 58 pharmacokinetic PK study 58 Hedgehog signaling pathway 58 poly ADP ribose polymerase 58 miR #a [001] 58 Valopicitabine 58 IMC #B 58 sCD# 58 DFMO 58 Gefitinib 58 NCCTG 58 DermaVir 58 Exelixis XL# 58 relapsed multiple myeloma 58 refractory CLL 58 Trastuzumab 58 ATL# [001] 58 RAV# 58 telomerase inhibitor 58 microRNA miR 58 iniparib 58 novel anticancer 58 FVIIa 58 compound AEZS 58 Ceflatonin 58 TG# [003] 58 cobiprostone 58 Galectin 58 PROSTVAC TM 58 LHRH antagonists 58 uricase 58 systemic RNAi therapeutic 58 Imetelstat 58 tyrosine kinase inhibitor 58 potently inhibit 58 #I TM# 58 Ocrelizumab 58 anticancer compound 58 JAK kinases 58 investigational oral hepatitis C 58 Neulasta ® 58 T#I mutant 58 refractory chronic lymphocytic 58 oral JAK1 58 pegylated interferon alfa 2a 58 metaglidasen 58 Panitumumab 58 HIF PHI 58 CDK4 58 CCR5 antagonist 58 docetaxel Taxotere 58 Aflibercept 58 TRIOLEX 58 EndoTAG TM 58 Boceprevir 58 taxane resistant 58 methionine aminopeptidase 58 preclinical 58 Eg5 58 crizotinib PF # 58 VitiGam 58 pegfilgrastim 58 CXCR7 58 trastuzumab DM1 T DM1 58 anaplastic lymphoma kinase ALK 58 vivo validation 58 EphA2 58 LUX Lung 58 bortezomib Velcade 58 oral picoplatin 58 tipifarnib 58 Azixa 58 panobinostat 58 IAP inhibitors 58 inhibitor ARRY 58 histone deacetylase HDAC 58 SOD1 58 RDEA# 58 corticosteroid dexamethasone 58 inhibit tumor 58 tgAAC# 58 CoFactor 58 humanised antibody 58 maribavir 58 varespladib 58 allogeneic cell 58 JAK2 inhibitor 58 inhibited tumor 58 potent antiviral 58 multikinase inhibitor 58 Presents Preclinical Data 58 neuroprotective properties 58 ATHX 58 CCR9 antagonist 58 adecatumumab 58 SERMs 58 dasatinib Sprycel 58 deforolimus 58 highly selective inhibitor 58 HCV genotypes 58 Perifosine 58 gastrointestinal stromal tumors GIST 58 RRM1 58 trabectedin 58 orthotopic model 58 TELINTRA 58 zanolimumab 58 vaccine GRNVAC1 58 Nexavar ® 58 anti angiogenic agent 58 NS4A 58 Phase 2b Clinical Trial 57 TRAIL receptors 57 Arranon 57 pharmacodynamic profile 57 DiLA2 57 ToGA 57 EGFR tyrosine kinase inhibitors 57 Allovectin 7 ® 57 ADI PEG 57 mTOR mammalian target 57 JAK1 57 Bendavia 57 VEGF receptors 57 MetAP2 57 cyclin dependent kinase 57 Afatinib 57 cetuximab Erbitux ® 57 leukotriene pathway 57 TheraCIM 57 omega interferon 57 radiolabeled monoclonal antibody 57 leukemia AML 57 IKK epsilon 57 ISF# 57 Xelox 57 panitumumab Vectibix 57 Solorel TM 57 paclitaxel Taxol 57 PTHrP 57 CaPre TM 57 ritonavir boosted 57 darapladib 57 constitutively activated 57 hypereosinophilic syndrome 57 Phase 1a clinical 57 TELCYTA 57 CLORETAZINE TM VNP#M 57 GPNMB 57 triterpenoids 57 anti PlGF 57 GVAX ® 57 H#N# VLP vaccine 57 Epothilone D 57 oral bioavailability 57 mitogen activated ERK kinase 57 Allovectin 7 R 57 TMC# [002] 57 BiTE antibody 57 RhuDex ® 57 Hsp# inhibitor 57 JAK2 inhibitors 57 polymerase inhibitors 57 ZOLINZA 57 MET RET 57 ceftazidime 57 pancreatic adenocarcinoma 57 EGFR inhibitors 57 fusion protein 57 Aliskiren 57 CCR5 mAb 57 CLL cells 57 Proxinium TM 57 Elotuzumab 57 MEDI 57 Valortim ® 57 brivaracetam 57 Panzem NCD 57 cytokine refractory 57 retapamulin 57 GRNCM1 57 ataluren 57 miR 57 AMD# [003] 57 human tumor xenografts 57 TLR7 57 FOLFOX chemotherapy 57 Lpathomab 57 Cyclosert 57 trastuzumab Herceptin ® 57 synthetic peptide 57 rindopepimut 57 docetaxel Taxotere ® 57 Aurora kinase inhibitor 57 BCR ABL 57 targeted antifolate 57 Cloretazine ® 57 KRN# 57 Phase #b/#a clinical 57 JAK2 57 effector functions 57 Tezampanel 57 NeuroVax TM 57 FUS1 57 human monoclonal antibody 57 bactericidal activity 57 inhibitor VX 57 PI3K/mTOR 57 HER1 57 TH# [003] 57 pharmacodynamic PD 57 sunitinib malate 57 Campath alemtuzumab 57 VAX# 57 torezolid 57 temozolomide TMZ 57 carfilzomib 57 ocular formulation 57 Aclidinium 57 proteasome inhibitors 57 metastatic colorectal 57 Peginterferon 57 Nanobody ® 57 small molecule inhibitor 57 cetuximab Erbitux R 57 hypoxia inducible factor 57 bortezomib Velcade R 57 KRAS mutations 57 posaconazole 57 Bortezomib 57 anticancer agent 57 R sorafenib tablets 57 CXA 57 irreversible inhibitor 57 oritavancin 57 Oral NKTR 57 HER-2/neu 57 FOLFOX6 57 paclitaxel cisplatin 57 Golimumab 57 Guanilib 57 virus AAV 57 S1P 57 Pegasys ® 57 anti CD# antibodies 57 inhibits protein synthesis 57 PD LID 57 Pharmacokinetic analyzes 57 EndoTAG 57 microtubule targeting 57 EndoTAGTM 1 57 daunorubicin 57 Pegylated Interferon 57 Phase Ib study 57 Phase IIa clinical 57 BARACLUDE R 57 Presents Preclinical 57 antifibrotic 57 UsiRNAs 57 MEK inhibitor ARRY 57 anti angiogenic 57 mGluR2 NAM 57 ESBA# 57 gastrin 57 Tesmilifene 57 xenografts 57 myeloma cells 57 gamma secretase inhibitor 57 immunomodulatory effects 57 ORMD 57 chemokine receptor 57 recurrent glioma 57 mycophenolate mofetil 57 lymphoid malignancies 57 rALLy clinical trial 57 CD# [002] 57 relapsed refractory multiple myeloma 57 RVX 57 VRX# [002] 57 IDH1 57 XL# [003] 57 Neugene 57 generation antisense inhibitor 57 perifosine 57 Janus Kinase 57 Zolinza 57 visilizumab 57 HER2 positive metastatic breast 57 selective orally bioavailable 57 PPARgamma 57 pharmacokinetic studies 57 Interferon alfa 57 Phase 1b trial 57 HCV polymerase inhibitors 57 Fibroblast Growth Factor Receptor 57 pharmacodynamic 57 glioblastoma cells 57 signal transduction inhibitor 57 aurora kinase inhibitor 57 midstage clinical 57 EGFR signaling 57 Ceflatonin R 57 Anticalin R 57 Glufosfamide 57 oncolytic virus therapy 57 tafamidis 57 potent antiproliferative 57 KRAS mutant 57 seliciclib CYC# 57 Targretin 57 alfa 2a 57 REP# 57 ixabepilone 57 c MET 57 reslizumab 57 Bruton tyrosine kinase 57 MEK Inhibitor 57 TNF α 57 anti CD# antibody 57 PC3 cells 57 GLP toxicology studies 57 Preclinical studies suggest 57 chimeric monoclonal antibody 57 Radilex 57 NFkB 57 ZACTIMA 57 interferon IFN 57 retaspimycin hydrochloride 57 chemically modified siRNA 57 antisense inhibitor 57 peptidic compound 57 telomerase reverse transcriptase 57 Voreloxin 57 monoclonal antibody 57 oral ridaforolimus 57 ara C 57 targeted tyrosine kinase 57 HCV 57 investigational protease inhibitor 57 TNFα 57 hepatitis C HCV 57 tumor regression 57 HDAC 57 potent antitumor 57 IGFBP2 57 GSK# [002] 57 pDNA vaccine 57 humanized antibody 57 dose cohorts 57 cleavable linker 57 tipranavir 57 MUC1 57 mGlu2 3 57 BRAF mutation 57 MDA MB 57 hTERT 57 Flt3 57 vascular disrupting 57 Allovectin 7 57 pan histone deacetylase 57 HuMax CD4 57 antiviral potency 57 CCR1 57 G#DT 57 deacetylase inhibitors 57 Triapine 57 selectively inhibits 57 Thiarabine 57 Reolysin 57 TNFerade 57 Azacitidine 57 ZYBRESTAT 57 hepatoma 57 Camptosar ® 57 prasugrel CS 57 iroxanadine 57 telaprevir dosed 57 triphendiol 57 CXCR4 57 potent anticancer 57 murine 57 antiangiogenic therapy 57 KB# [002] 57 dasatinib Sprycel ® 57 oncolytic viruses 57 non nucleoside 57 neutralizing antibody 57 OMP #R# 57 TOCOSOL Paclitaxel 56 vorinostat 56 HCV RESPOND 2 56 interferon beta 56 bleomycin 56 galiximab 56 PI3K/Akt pathway inhibitor 56 CD#L 56 personalized immunotherapy 56 tkRNAi 56 cyclin E 56 pitavastatin 56 small molecule inhibitors 56 GMX# 56 pharmacodynamic markers 56 OncoVEX 56 CD# antigen 56 antiviral efficacy 56 IgG1 monoclonal antibody 56 alpha#beta# 56 ularitide 56 BiTE ® 56 PTP 1B 56 rFIXFc 56 Taxotere ® 56 estramustine 56 MGCD# [002] 56 BRAF kinase 56 prostate cancer mCRPC 56 MAPK pathway 56 Potelligent Technology 56 CEQ# 56 TRAIL receptor 56 RAS MAPK pathway 56 HDAC inhibition 56 IAP inhibitor 56 bafetinib 56 indibulin 56 Omacetaxine mepesuccinate 56 TLR7 agonist 56 cediranib